Literature DB >> 28781151

2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan.

Bor-Sheng Ko1, Wei-Ting Chen2, Hsiang-Chi Kung3, Un-In Wu3, Jih-Luh Tang1, Ming Yao4, Yee-Chun Chen5, Hwei-Fang Tien4, Shan-Chwen Chang6, Yin-Ching Chuang7, Dong-Tsamn Lin8.   

Abstract

The Infectious Diseases Society of Taiwan (IDST), the Hematology Society of Taiwan, the Taiwan Society of Blood and Marrow Transplantation, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, and CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines cooperatively published this guideline for the use of antifungal agents in hematological patients with invasive fungal diseases (IFDs) in Taiwan. The guideline is the first one endorsed by IDST focusing on selection of antifungal strategies, including prophylaxis, empirical (or symptom-driven) and pre-emptive (or diagnostic-driven) strategy. We suggest a risk-adapted dynamic strategy and provide an algorithm to facilitate decision making in population level as well as for individual patient. Risk assessment and management accordingly is explicitly emphasized. In addition, we highlight the importance of diagnosis in each antifungal strategy among five elements of the antimicrobial stewardship (diagnosis, drug, dose, de-escalation and duration). The rationale, purpose, and key recommendations for the choice of antifungal strategy are summarized, with concise review of international guidelines or recommendation, key original articles and local epidemiology reports. We point out the interaction and influence between elements of recommendations and limitation of and gap between evidences and daily practice. The guideline balances the quality of evidence and feasibility of recommendation in clinical practice. Finally, this version introduces the concept of health economics and provides data translated from local disease burdens. All these contents hopefully facilitate transparency and accountability in medical decision-making, improvements in clinical care and health outcomes, and appropriateness of medical resource allocation.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Antifungal stewardship; Antifungal strategy; De-escalation; Definitive therapy; Diagnosis-driven strategy; Empirical therapy; Health economic; Preemptive therapy; Prophylaxis; Risk assessment; Symptom-driven strategy; Therapeutic algorithm

Mesh:

Substances:

Year:  2017        PMID: 28781151     DOI: 10.1016/j.jmii.2017.07.005

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  3 in total

1.  Epidemiology of Aspergillosis in Cancer Patients in Taiwan.

Authors:  Chien-An Chen; Chung-Han Ho; Yu-Cih Wu; Yi-Chen Chen; Jhi-Joung Wang; Kuang-Ming Liao
Journal:  Infect Drug Resist       Date:  2022-07-13       Impact factor: 4.177

2.  Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis.

Authors:  Hui-Chen Su; Yi-Ming Hua; I Jung Feng; Hung-Chang Wu
Journal:  Infect Drug Resist       Date:  2019-05-15       Impact factor: 4.003

3.  The Value of Nasal and Oral Clinical Examination in Febrile Neutropenic Patients for Initiating Antifungal Therapy as a Preemptive Method.

Authors:  Mohammadreza Salehi; Sara Ghaderkhani; Ramezan Ali Sharifian; Seyed Ali Dehghan Manshadi; Elahe Samiee Fard; Sadegh Khodavaisy; Ramtin Pourahmad; Abbas Rahimi Foroushani; Kamran Rodini; Hasti Kamali Sarvestani
Journal:  Front Med (Lausanne)       Date:  2022-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.